Member Info for harley24

Seems to be recruiting, so business can’t be so bad.. Still a risk... but...

aware of the risk but decided to join today after doing a bit of research - high risk but equally could be very high reward. Quite like the background of Martin Lampshire.. seems more going for PSL than against.. I guess we will find out over next 2 weeks. GLA

Well I certainly am..

It was a direct response to a question about phase 3.

so confirmed as a peer review - hope this clarifies for the other who were doubting.. Would have been nice to see a summary translated into laymen's language for us none techy's but I gleaned enough to be satisfied when I read it yesterday.. GLA

Adam, we seem to agree now... :)

Valu, maybe this is the catalyst for the deal to move to the next step...

yes we did but didn't really get any info about content.. now we have it. but feel maybe there should be a summary published in laymen's term for us shareholders.. hope this will happen shortly..

oxmil, maybe that's why there is no RNS... none of us really understand the details - I have just gleaned what I believe to be a bit clear to me. maybe a more 'simple' version is being drafted for our benefit and will be RNS'd a bit later..?

This is why there are a number of steps... people seem to think we can jump from preclinical to launch without a thorough understanding.. Personally I am happy with this conclusion for further studies for 401 cancer treatment..

'Conclusions Further comparisons of the pharmacokinetic parameters of risperidone and 9-hydroxyrisperidone in plasma of
patients administered VAL401 and the corresponding parameters obtained from published data for conventionally formulated
risperidone provide evidence for altered biological processing of VAL401 as compared to risperidone. The absolute values
obtained provide support for future studies of VAL401 as a cancer treatment, as the Cmax demonstrates sufficient exposure
to reach the concentrations seen during preclinical anticancer testing, yet the overall exposure to the active moiety supports
the use of the safety and tolerability data from conventional risperidone during future clinical trials'

oxmil, read the question from Adam...she is directly responding to his question re phase 3...

click on 'members' above and then click on 'private messenger'.. it should show you my message to you...just respond with your email address..

I just sent you a direct message . was sent ok...just check.

difficult to copy and paste conversation - can you send me your email on LSE private message and I will try and send you screen shot if it helps..

read her response to Adam.. its there..

agree - lets see eh... Comment from Dilly on Linkedin suggest phase 3 plans are underway..

roses, no it don't say that - its your interpretation and as always will try and find a negative spin on this. yes it wold provide further information so would Phase 3..there is no comment suggesting more Ph 2 trials are needed..

Wow, nice find...surely should be an rns from Val re this...

Seems like there could be some government funds coming our way in my view... so roses, you may be right about funding, but not in the dilutive manner - happy days :)

'With ValiRx currently developing precision therapeutics for hormone induced cancers coupled with new technology for early detection, the Company is delighted to be among the front runners contributing to this government and NHS-led initiative'

oil-beast, I think I would rather read what forsight is sending than all the other dross being spouted on here. anyway, good luck and here's hoping for a nice recovery soon!